950160 — Kolon TissueGene Balance Sheet
0.000.00%
- KR₩63tn
- KR₩63tn
- $3.63m
Annual balance sheet for Kolon TissueGene, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 32.9 | 46 | 21.3 | 0.546 | 57.2 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.289 | 0.582 | 1.07 | 0.18 | 0.424 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 36.7 | 49.8 | 24.8 | 5.04 | 60.1 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 7.55 | 6.44 | 5.48 | 4.74 | 4.27 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 51.8 | 86.7 | 105 | 151 | 295 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 13.6 | 9.16 | 11.1 | 48.4 | 248 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 19.2 | 14.5 | 15.5 | 52 | 251 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| ESOP Debt Guarantee | |||||
| Other Equity | |||||
| Total Equity | 32.6 | 72.2 | 89.2 | 99.3 | 44.7 |
| Total Liabilities & Shareholders' Equity | 51.8 | 86.7 | 105 | 151 | 295 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |